A Randomized, Double Blind, Comparative, Phase II/III Study to Evaluate the Immunogenicity and Safety of Three Formulations [15 mcg (unadjuvanted), 7.5 mcg (adjuvanted) and 3.75 mcg (adjuvanted)] of Monovalent H1N1 Influenza A (2009) Virus Vaccine, Manufactured by Panacea Biotec Ltd., in Healthy Pediatric Population 3 - 9 Years of Age.
Phase of Trial: Phase II/III
Latest Information Update: 03 Mar 2011
At a glance
- Drugs Adjuvants; Influenza A virus vaccine-H1N1
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Panacea Biotec